Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Kaleido Biosciences Inc

(NASDAQ: KLDO)
Add to Portfolio
-0.40 (-7.34%)
as of Oct 18, 2019

Last 5.05
Change -0.40 (-7.34%)
Open 5.40
Prev. Close 5.45
Today's Range
4.82
5.45
52wk Range
4.80
19.00
Volume 93,100
Avg Volume 60,895
Sector Medical - Biomedical

Perfomance Comparison

Name Today 3-Month 1-Year
KLDO -7.34% -40.02% -64.51%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS N/A
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 162,590
Weighted Alpha -72.50
Standard Deviation -1.80
Profit Margin N/A
Beta N/A

Growth Rates

YTD -64.51%

Opinion

Sell Hold Buy

Recent Headlines

Kaleido Biosciences Announces Appointment of Jean

GlobeNewswire via COMTEX - Mon Sep 30, 08:01AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Jean Mixer has been (full story)
KLDO: 5.05 (-0.40)

Kaleido Biosciences to Present at the Morgan Stanley

GlobeNewswire via COMTEX - Thu Aug 29, 08:00AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that management will part(full story)
MS: 43.66 (+0.22), KLDO: 5.05 (-0.40)

Kaleido Biosciences Announces Appointment of Theo

GlobeNewswire via COMTEX - Mon Jul 15, 08:00AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that The(full story)
KLDO: 5.05 (-0.40), EVLO: 6.53 (-0.16)

Kaleido Biosciences Announces Closing of Initial

GlobeNewswire via COMTEX - Mon Mar 04, 04:22PM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today an(full story)
MS: 43.66 (+0.22), KLDO: 5.05 (-0.40)

Nasdaq Welcomes Kaleido Biosciences, Inc. (Nasdaq:

GlobeNewswire via COMTEX - Thu Feb 28, 11:30AM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health, (full story)
KLDO: 5.05 (-0.40), NDAQ: 98.62 (+0.29)